Takeda Pharmaceutical has agreed to sell its laboratory reagents business, Wako Pure Chemical Industries, to Fujifilm in a tender offer bid to be launched by Fujifilm in late February with a sale price of Japanese Yen 198.5 billion ($1.7 billion).

The move is in line with Takeda’s strategy to focus its research and development efforts on oncology, gastroenterology, central nervous system diseases, and vaccines with the goal of achieving sustainable growth as a global pharmaceutical company. To meet this goal, Takeda has decided to sell the Wako Pure Chemical business to Fujifilm, which already has a long-term relationship with the business and has a mid- to long-term growth strategy centered on healthcare and functional materials. Wako Pure Chemical was established in 1922 with the spin-off of the chemical agent division of Takeda.

Source: Takeda Pharmaceutical